Cargando…

OR34-03 Defining Clinical Characteristics Of Patients With Severe Hypoglycemia After Roux-en-Y Gastric Bypass: How Do They Differ From Asymptomatic Patients?

Disclosure: A. Grover: None. A.L. Sheehan: None. C. Cummings: None. M. Farahmandsadr: None. H. Saeed: None. A.M. Puleio: None. D.C. Simonson: Stock Owner; Self; Phase V Technologies, GI Windows. M. Patti: Consulting Fee; Self; AstraZeneca, MBX-Biosciences, Hanmi Pharmaceutical. Other; Self; DSMB: Fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Grover, Ashna, Sheehan, Amanda Lyn, Cummings, Cameron, Farahmandsadr, Maryam, Saeed, Hamayle, Puleio, Alexa Marie, Simonson, Donald Craig, Patti, Mary-Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555740/
http://dx.doi.org/10.1210/jendso/bvad114.1042
_version_ 1785116724395245568
author Grover, Ashna
Sheehan, Amanda Lyn
Cummings, Cameron
Farahmandsadr, Maryam
Saeed, Hamayle
Puleio, Alexa Marie
Simonson, Donald Craig
Patti, Mary-Elizabeth
author_facet Grover, Ashna
Sheehan, Amanda Lyn
Cummings, Cameron
Farahmandsadr, Maryam
Saeed, Hamayle
Puleio, Alexa Marie
Simonson, Donald Craig
Patti, Mary-Elizabeth
author_sort Grover, Ashna
collection PubMed
description Disclosure: A. Grover: None. A.L. Sheehan: None. C. Cummings: None. M. Farahmandsadr: None. H. Saeed: None. A.M. Puleio: None. D.C. Simonson: Stock Owner; Self; Phase V Technologies, GI Windows. M. Patti: Consulting Fee; Self; AstraZeneca, MBX-Biosciences, Hanmi Pharmaceutical. Other; Self; DSMB: Fractyl Health, Inc. Introduction: Post-bariatric hypoglycemia (PBH) is a severe, disabling complication of Roux-en-Y gastric bypass (RYGB). We aimed to identify clinical characteristics distinguishing patients with severe PBH vs. post-RYGB patients without symptomatic hypoglycemia (RYGB non-hypo) to help elucidate PBH pathophysiology and potential risk factors. Methods: Adults aged 18-70, without diabetes mellitus (DM), were recruited into 3 groups: (1) PBH with neuroglycopenia (n=33); (2) RYGB non-hypo (n=16); (3) non-surgical weight-matched controls (n=17). Detailed history of hypoglycemia, medical/surgical/family history, medications, Dumping Symptom Rating Scale (DSRS), and Rome IV diagnostic criteria for Irritable Bowel Syndrome (IBS) was completed. Differences between PBH and RYGB non-hypo were evaluated by unpaired t-tests and chi-square analysis as indicated. Results: PBH participants were 90% female, mean age 53±2 y, BMI 32±1 kg/m2, 39±2% body fat, with similar data for RYGB non-hypo (100% female, age 54±2 y, BMI 33±2 kg/m2, 40±2% fat), and controls (65% female, age 45±4 y, BMI 31±2 kg/m2, 35±3% fat). 90% of PBH reported level 3 hypoglycemia, with ER visits in 29% and motor vehicle accidents in 7%. Reduced awareness of hypoglycemia was reported by 80% of PBH, with hypoglycemia awareness at mean glucose of 57±2 mg/dL. 29% of PBH reported hypoglycemic symptoms occurring preoperatively, and 20% reported family history of hypoglycemia. The majority of PBH reported depression, change in driving habits, and adverse impact on employment. When compared with RYGB non-hypo, PBH participants had no difference in postoperative weight loss trajectories but had higher prevalence of revisional surgeries (p<0.05). PBH participants also had a higher score on DSRS (p<0.05) and higher prevalence of IBS (48 vs. 7% meeting Rome IV criteria, p<0.05). Higher rates of orthostatic hypotension, intestinal dysmotility, and vitamin B12 deficiency requiring treatment were reported by PBH (p<0.05 for all). Additionally, PBH participants reported greater gabapentin, PPI, and hormonal contraceptive use (p<0.05 for all); there were no differences in SSRI/SNRI use. Conclusion: PBH participants reported high rates of hypoglycemia unawareness, a likely contributor to hypoglycemia severity, recurrence, and adverse effects on safety and personal life. High rates of IBS, dumping symptoms, and orthostatic hypotension suggest possible disordered autonomic regulation in the pathophysiology of PBH. Self-reported preoperative symptoms and family history of hypoglycemia suggest possible differences in glucose metabolism prior to surgery in at-risk individuals. Preoperative assessment of these and other factors, together with longitudinal follow-up studies to determine incidence of PBH, will be required to identify risk factors for development of post-bariatric hypoglycemia. Presentation: Sunday, June 18, 2023
format Online
Article
Text
id pubmed-10555740
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105557402023-10-07 OR34-03 Defining Clinical Characteristics Of Patients With Severe Hypoglycemia After Roux-en-Y Gastric Bypass: How Do They Differ From Asymptomatic Patients? Grover, Ashna Sheehan, Amanda Lyn Cummings, Cameron Farahmandsadr, Maryam Saeed, Hamayle Puleio, Alexa Marie Simonson, Donald Craig Patti, Mary-Elizabeth J Endocr Soc Diabetes And Glucose Metabolism Disclosure: A. Grover: None. A.L. Sheehan: None. C. Cummings: None. M. Farahmandsadr: None. H. Saeed: None. A.M. Puleio: None. D.C. Simonson: Stock Owner; Self; Phase V Technologies, GI Windows. M. Patti: Consulting Fee; Self; AstraZeneca, MBX-Biosciences, Hanmi Pharmaceutical. Other; Self; DSMB: Fractyl Health, Inc. Introduction: Post-bariatric hypoglycemia (PBH) is a severe, disabling complication of Roux-en-Y gastric bypass (RYGB). We aimed to identify clinical characteristics distinguishing patients with severe PBH vs. post-RYGB patients without symptomatic hypoglycemia (RYGB non-hypo) to help elucidate PBH pathophysiology and potential risk factors. Methods: Adults aged 18-70, without diabetes mellitus (DM), were recruited into 3 groups: (1) PBH with neuroglycopenia (n=33); (2) RYGB non-hypo (n=16); (3) non-surgical weight-matched controls (n=17). Detailed history of hypoglycemia, medical/surgical/family history, medications, Dumping Symptom Rating Scale (DSRS), and Rome IV diagnostic criteria for Irritable Bowel Syndrome (IBS) was completed. Differences between PBH and RYGB non-hypo were evaluated by unpaired t-tests and chi-square analysis as indicated. Results: PBH participants were 90% female, mean age 53±2 y, BMI 32±1 kg/m2, 39±2% body fat, with similar data for RYGB non-hypo (100% female, age 54±2 y, BMI 33±2 kg/m2, 40±2% fat), and controls (65% female, age 45±4 y, BMI 31±2 kg/m2, 35±3% fat). 90% of PBH reported level 3 hypoglycemia, with ER visits in 29% and motor vehicle accidents in 7%. Reduced awareness of hypoglycemia was reported by 80% of PBH, with hypoglycemia awareness at mean glucose of 57±2 mg/dL. 29% of PBH reported hypoglycemic symptoms occurring preoperatively, and 20% reported family history of hypoglycemia. The majority of PBH reported depression, change in driving habits, and adverse impact on employment. When compared with RYGB non-hypo, PBH participants had no difference in postoperative weight loss trajectories but had higher prevalence of revisional surgeries (p<0.05). PBH participants also had a higher score on DSRS (p<0.05) and higher prevalence of IBS (48 vs. 7% meeting Rome IV criteria, p<0.05). Higher rates of orthostatic hypotension, intestinal dysmotility, and vitamin B12 deficiency requiring treatment were reported by PBH (p<0.05 for all). Additionally, PBH participants reported greater gabapentin, PPI, and hormonal contraceptive use (p<0.05 for all); there were no differences in SSRI/SNRI use. Conclusion: PBH participants reported high rates of hypoglycemia unawareness, a likely contributor to hypoglycemia severity, recurrence, and adverse effects on safety and personal life. High rates of IBS, dumping symptoms, and orthostatic hypotension suggest possible disordered autonomic regulation in the pathophysiology of PBH. Self-reported preoperative symptoms and family history of hypoglycemia suggest possible differences in glucose metabolism prior to surgery in at-risk individuals. Preoperative assessment of these and other factors, together with longitudinal follow-up studies to determine incidence of PBH, will be required to identify risk factors for development of post-bariatric hypoglycemia. Presentation: Sunday, June 18, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10555740/ http://dx.doi.org/10.1210/jendso/bvad114.1042 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Diabetes And Glucose Metabolism
Grover, Ashna
Sheehan, Amanda Lyn
Cummings, Cameron
Farahmandsadr, Maryam
Saeed, Hamayle
Puleio, Alexa Marie
Simonson, Donald Craig
Patti, Mary-Elizabeth
OR34-03 Defining Clinical Characteristics Of Patients With Severe Hypoglycemia After Roux-en-Y Gastric Bypass: How Do They Differ From Asymptomatic Patients?
title OR34-03 Defining Clinical Characteristics Of Patients With Severe Hypoglycemia After Roux-en-Y Gastric Bypass: How Do They Differ From Asymptomatic Patients?
title_full OR34-03 Defining Clinical Characteristics Of Patients With Severe Hypoglycemia After Roux-en-Y Gastric Bypass: How Do They Differ From Asymptomatic Patients?
title_fullStr OR34-03 Defining Clinical Characteristics Of Patients With Severe Hypoglycemia After Roux-en-Y Gastric Bypass: How Do They Differ From Asymptomatic Patients?
title_full_unstemmed OR34-03 Defining Clinical Characteristics Of Patients With Severe Hypoglycemia After Roux-en-Y Gastric Bypass: How Do They Differ From Asymptomatic Patients?
title_short OR34-03 Defining Clinical Characteristics Of Patients With Severe Hypoglycemia After Roux-en-Y Gastric Bypass: How Do They Differ From Asymptomatic Patients?
title_sort or34-03 defining clinical characteristics of patients with severe hypoglycemia after roux-en-y gastric bypass: how do they differ from asymptomatic patients?
topic Diabetes And Glucose Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555740/
http://dx.doi.org/10.1210/jendso/bvad114.1042
work_keys_str_mv AT groverashna or3403definingclinicalcharacteristicsofpatientswithseverehypoglycemiaafterrouxenygastricbypasshowdotheydifferfromasymptomaticpatients
AT sheehanamandalyn or3403definingclinicalcharacteristicsofpatientswithseverehypoglycemiaafterrouxenygastricbypasshowdotheydifferfromasymptomaticpatients
AT cummingscameron or3403definingclinicalcharacteristicsofpatientswithseverehypoglycemiaafterrouxenygastricbypasshowdotheydifferfromasymptomaticpatients
AT farahmandsadrmaryam or3403definingclinicalcharacteristicsofpatientswithseverehypoglycemiaafterrouxenygastricbypasshowdotheydifferfromasymptomaticpatients
AT saeedhamayle or3403definingclinicalcharacteristicsofpatientswithseverehypoglycemiaafterrouxenygastricbypasshowdotheydifferfromasymptomaticpatients
AT puleioalexamarie or3403definingclinicalcharacteristicsofpatientswithseverehypoglycemiaafterrouxenygastricbypasshowdotheydifferfromasymptomaticpatients
AT simonsondonaldcraig or3403definingclinicalcharacteristicsofpatientswithseverehypoglycemiaafterrouxenygastricbypasshowdotheydifferfromasymptomaticpatients
AT pattimaryelizabeth or3403definingclinicalcharacteristicsofpatientswithseverehypoglycemiaafterrouxenygastricbypasshowdotheydifferfromasymptomaticpatients